GlassScriptPhysician profile
Darin Dean Dougherty
NPI 1619968286
$26,678.43
in general payments reported to CMS, 2019-2025
15 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,543 · 2020: $500 · 2022: $6,265 · 2023: $11K · 2024: $412 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,750 · Travel and Lodging: $3,294 · Consulting Fee: $2,225 · Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,750.00 |
| Travel and Lodging | $3,294.24 |
| Consulting Fee | $2,225.00 |
| Food and Beverage | $1,100.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $8,769.22 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Medtronic USA, INC. | $6,543.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,215.82 | 2022-2023 | |
| Biogen, INC. | $2,658.00 | 2022 | |
| Omniscient Neurotechnology America LTD | $2,250.00 | 2022 | |
| Neurocrine Biosciences, INC. | $1,964.05 | 2025 | |
| Allergan, INC. | $500.00 | 2020 | |
| Abbott Laboratories | $411.64 | 2024 | Infinity |
| Immedica Pharma US, INC. | $366.67 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.